Gossamer Bio (NASDAQ:GOSS) Price Target Cut to $2.00 by Analysts at HC Wainwright

Gossamer Bio (NASDAQ:GOSS) had its price objective cut by research analysts at HC Wainwright from $5.00 to $2.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Other equities analysts have also recently issued reports about the stock. Oppenheimer lowered their price target on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Weiss Ratings cut shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Gossamer Bio in a research note on Monday, March 23rd. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.50.

Gossamer Bio Stock Up 1.2%

Shares of GOSS stock traded up $0.00 during trading hours on Thursday, reaching $0.17. 4,528,755 shares of the stock traded hands, compared to its average volume of 13,593,133. Gossamer Bio has a 1-year low of $0.14 and a 1-year high of $3.87. The firm has a market capitalization of $40.13 million, a PE ratio of -0.22 and a beta of 2.00. The business has a fifty day moving average price of $0.27 and a 200 day moving average price of $1.31.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $16.95 million for the quarter, compared to the consensus estimate of $4.67 million. Research analysts expect that Gossamer Bio will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Gossamer Bio

Several institutional investors have recently modified their holdings of GOSS. Tudor Investment Corp ET AL raised its stake in shares of Gossamer Bio by 7.8% in the third quarter. Tudor Investment Corp ET AL now owns 50,103 shares of the company’s stock valued at $132,000 after purchasing an additional 3,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Gossamer Bio by 24.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,964 shares of the company’s stock valued at $74,000 after buying an additional 4,767 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in shares of Gossamer Bio by 22.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after buying an additional 4,771 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Gossamer Bio by 0.4% in the 4th quarter. Deutsche Bank AG now owns 1,284,335 shares of the company’s stock valued at $3,981,000 after buying an additional 5,414 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its holdings in shares of Gossamer Bio by 52.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock worth $74,000 after acquiring an additional 8,239 shares during the period. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.